Page last updated: 2024-11-04

vorinostat and Fibroid

vorinostat has been researched along with Fibroid in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Prospective study comparing uterine leiomyoma (UL) vs."1.72Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma. ( Carbajo-García, MC; Corachán, A; Faus, A; Ferrero, H; García-Alcázar, Z; Monleón, J; Pellicer, A; Trelis, A, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Carbajo-García, MC1
García-Alcázar, Z1
Corachán, A1
Monleón, J1
Trelis, A1
Faus, A1
Pellicer, A1
Ferrero, H1

Other Studies

1 other study available for vorinostat and Fibroid

ArticleYear
Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
    Fertility and sterility, 2022, Volume: 117, Issue:2

    Topics: Adult; Antineoplastic Agents; Cell Cycle; Cell Proliferation; Extracellular Matrix; Female; Gene Exp

2022